Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells

Blood

Volumn 97, Issue 10, 2001, Pages 3138-3145

  Notter, Michael ^a   Willinger, Tim ^a   Erben, Ulrike ^a   Thiel, Eckhard ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN G; T LYMPHOCYTE ANTIGEN;

ARTICLE; BINDING KINETICS; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMOBILIZED CELL; LEUKEMIA CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL CULTURE;

EID: 0035874549     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.10.3138     Document Type: Article

References (27)

1. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068.
2. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555.
3. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041.
4. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med. 1994;330:1185.
5. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233.
6. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol. 1997;9:396.
7. Dunussi-Joannopoulos K, Krenger W, Weinstein HJ, Ferrara JL, Croop JM. CD8+ T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment. Blood. 1997;89:2915.
8. Boyer MW, Vallera DA, Taylor PA, et al. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties. Blood. 1997;89:3477.
9. Matulonis U, Dosiou C, Freeman GJ, et al. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. J Immunol. 1996;156:1126.
10. Seed B, Aruffo A. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci U S A. 1987;84:3365.
11. Cardoso AA, Schultze JL, Boussiotis VA, et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996;88:41.
12. Hirano N, Takahashi T, Takahashi T, et al. Expression of costimulatory molecules in human leukemias. Leukemia. 1996;10:1168.
13. Azuma M, Ito D, Yagita H, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993;366:76.
14. Maeda A, Yamamoto K, Yamashita K, et al. The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2-positive leukaemia. Br J Haematol. 1998;102:1257.
15. Gajewski TF. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol. 1996;156:465.
16. Olsson C, Michaelsson E, Parra E, Pettersson U, Lando PA, Dohisten M. Biased dependency of CD80 versus CD86 in the induction of transcription factors regulating the human IL-2 promoter. Int Immunol. 1998;10:499.
17. Greenfield EA, Howard E, Paradis T, et al. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding. J Immunol. 1997;158:2025.
18. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin-2 mRNA accumulation. J Exp Med. 1991;173:721.
19. van de Winkel JGJ, Capel PJA. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today. 1993;14:215.
20. Notter M, Ludwig WD, Bremer S, Thiel E. Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells. Blood. 1993;82:3113.
21. Olweus J, Lund-Johansen F, Terstappen LWMM. CD64/Fc gamma RI is a granulo-monocytic lineage marker on CD34+ hematopoietic progenitor cells. Blood. 1995;85:2402.
22. Ohnishi K, Yamanishi H, Naito K, et al. Reconstitution of peripheral blood lymphocyte subsets in the long-term disease-free survivors of patients with acute myeloblastic leukemia. Leukemia. 1998;12:52.
23. Buggins AGS, Hirst WJR, Pagliuca A, Mufti GJ. Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. Br J Haematol. 1998;100:784.
24. Croft M, Dubey C. Accessory molecule and costimulation requirements for CD4 T cell response. Crit Rev Immunol. 1997;17:89.
25. Hirst WJA, Buggins A, Darling D, Gaken J, Farzaneh F, Mufti GJ. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1. Gene Ther. 1997;4:691.
26. Mutis T, Schrama E, Melief CJ, Goulmy E. CD80-transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens. Blood. 1998;92:1677.
27. Choudhury BA, Liang JC, Thomas EK, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 1999;93:780.